Italia markets close in 39 minutes

FTSE MIB
34.586,13
-238,88(-0,69%)
Dow Jones
39.855,69
+48,92(+0,12%)
Nasdaq
16.787,39
-7,49(-0,04%)
Nikkei 225
38.946,93
-122,75(-0,31%)
Petrolio
79,34
-0,46(-0,58%)
Bitcoin EUR
64.837,64
+3.295,58(+5,36%)

NVCR Jan 2026 10.000 put

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

1,8000

0,0000

(0,00%)

In data: 12:55PM EDT. Mercato aperto.

GlobeNewswire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in